


Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

What is claimed is:

1. **(Currently Amended)** A compound of formula (I):



wherein:

R¹ is optionally substituted -C₄₋₁₂ alkyl, -C₂₋₁₀alkylcycloalkyl, C₂₋₆alkylheterocycloalkyl, -C₂₋₆alkylaryl, optionally substituted 5- or 6- membered aryl or heteroaryl with the proviso that R² is not pyridinyl;

Z is a bond, CH₂, O, S, SO, SO₂, NR⁴, OCR⁴R⁵ or CR⁴R⁵O; or Z, R¹ and Q together form an optionally substituted fused tricyclic group;

Q is an optionally substituted 5- or 6- membered aryl or heteroaryl ring;

X is COR³;

R² is CONH₂, CO₂H, CO₂R⁷, SO₂R⁷ or SO₂NR⁸R⁹,

~~with the proviso provided~~ that R² is not CO₂R⁷, when X is CONH₂;
R³ is OR⁶ or NR⁸R⁹;

R⁴ and R⁵ each independently is H, C₁₋₆ alkyl or C₁₋₄ alkylaryl;

R⁶ is H or C₁₋₆ alkyl;

R⁷ is C₁₋₆ alkyl; and

R⁸ and R⁹ each independently is H or C₁₋₆ alkyl; or R⁸ and R⁹ together with the nitrogen atom to which they are attached form a 5- or 6- membered ring which may optionally include 1 or more further heteroatoms selected from O, S and N;
or

physiologically functional derivatives thereof,

~~with the proviso provided~~ that formula (I) compounds are not:


[3-(acetylamino)-4-cyclohexylphenyl]-butanedioic acid and 3-(acetylamino)-4-cyclohexylphenyl]-butanedioic acid diethyl ether;

butanedioic acid [3-methoxy-4-(phenylmethoxy)phenyl]; or

butanedioic acid [4-(phenylmethoxy)phenyl]; and

~~with the proviso further provided~~ that when R¹ is C₄₋₁₂alkyl, Z is other than a bond, O or CH₂, or physiologically functional derivatives thereof.

2. (Previously Presented) A compound as claimed in claim 1 wherein X is CO₂H and R² represents CONH₂.
3. (Previously Presented) A compound as claimed in claim 1 wherein Q is an unsubstituted phenyl.
4. (Previously Presented) A compound as claimed in claim 1 wherein Z represents a bond or O.
5. (Previously Presented) A compound as claimed in claim 1 of formula (Ia):




wherein R¹³ is H, halo, CF₃, -OCF₃, cyano, nitro, OR¹⁴, SR¹⁵ or COR¹⁶; and R¹⁴, R¹⁵, R¹⁶ independently are H, C₁₋₆ alkyl or C₁₋₄ alkylaryl; or physiologically functional derivatives thereof.

6. (Cancelled)
7. (Previously Presented) A method for the treatment of a human or animal subject suffering from or susceptible to an inflammatory disease or an autoimmune disorder which method comprises administering to said subject an effective amount of a compound as claimed in claim 1.
8. (Cancelled)
9. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 1 and a pharmaceutically acceptable carrier.


10. **(Currently Amended)** A process for ~~the~~ preparation of compounds of formula (I) as defined in claim 1, ~~which wherein the~~ process comprises:

(A) ~~for~~ preparing a compound of formula (I), wherein Z is a bond and R¹ is an optionally substituted 5- or 6- membered aryl or heteroaryl, ~~by~~ reacting a compound of formula (II):



wherein R², Q and X are as previously defined for formula (I) and L¹ is a leaving group, ~~with a reagent suitable to introduce the group R¹; or~~

(B) (i) ~~for~~ preparing a compound of formula (I), wherein Z is O, S, SO, SO₂, NR⁴ or OCR⁴R⁵, by reacting a compound of formula (III):



wherein R², Q and X are as previously defined for formula (I) and Y is OH, SH, NHR⁴ or HOCHR⁴R⁵, with a compound of formula (IV):



wherein R¹ is defined above for compounds of formula (I) and L² represents a leaving group; and

(ii) ~~wherein~~ Y is -SH, optionally followed by ~~oxidation oxidizing the Y group~~ to the corresponding SO or SO₂ ~~group~~ as required; or


(C) ~~for~~ preparing a compound of formula (I), wherein Z is -CR⁴R⁵O-, by reacting a compound of formula (III), wherein Y is -OH, with a compound of formula (V):



wherein R¹ R⁴, R⁵ are defined above for compounds of formula (I) and L³ represents a leaving group; or

(D) ~~for~~ preparing a compound of formula (I), wherein Z is CH₂ and R¹ is an optionally substituted 5- or 6- membered aryl or heteroaryl, by reacting

_____ (i) a compound of formula (VI):



wherein Q, X and R² are as defined above, with an optionally substituted 5- or 6- membered aryl or heteroaryl nucleophile, which is a compound of formula (VII):



(VII)

wherein A is a 5- or 6- membered aryl or heteroaryl, R¹⁷ is H or one or more substituents and M is a metal and

_____ (ii) reduction and elimination reducing and eliminating of the a resultant or product alcohol formed from step (i); and, if necessary,

(E) ~~deprotection~~ optionally deprotecting of a ~~protected form~~ of compounds of formula (I) with a protecting group.